PR Newswire – Page 3250

Brand Post June 2, 2024

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical…

Brand Post June 2, 2024

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical…

Brand Post June 2, 2024

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical…

Brand Post June 1, 2024

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology…

Brand Post June 1, 2024

LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®

MILLIONS TUNED IN FROM ACROSS THE WORLD TO SEE THE LEGENDARY ARTIST'S UNFORGETTABLE PERFORMANCE AHEAD OF THE BIGGEST GAME IN…

Brand Post June 1, 2024

Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month

MIAMI, June 1, 2024 /PRNewswire/ -- Today, Sun Bum made waves in Miami with its largest ever beach hangout, marking…

Brand Post June 1, 2024

Media Advisory – Deputy Prime Minister’s itinerary for Sunday, June 2, 2024

OTTAWA, ON, June 1, 2024 /CNW/ - Note: All times local. Toronto, Ontario Private meetings. 12:30 p.m. The Deputy…

Brand Post June 1, 2024

Media Advisory – Prime Minister’s itinerary for Sunday, June 2, 2024

OTTAWA, ON, June 1, 2024 /CNW/ - Note: All times local National Capital Region, Canada No public events scheduled This…

Brand Post June 1, 2024

Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation

-Data demonstrates durable responses across 3 cohorts of patients with recurrent and newly diagnosed GBM- -Data supports continued clinical development…

Brand Post June 1, 2024

BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025

DALLAS, June 1, 2024 /PRNewswire/ -- STEMREGENⓇ, the trailblazer in stem cell science-backed supplements that support the body's innate repair…

Brand Post June 1, 2024

Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting

CHICAGO, June 1, 2024 /PRNewswire/ -- On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products…

Brand Post June 1, 2024

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months…